Nancy. you, Thank
We MDS pleased our the whose the are efforts by tamibarotene, AML selective our in RAR-alpha of with overexpression potent higher-risk to and novel, agonist by progress characterized of RARA oral, subsets patients very in advance the is disease defined genomically and gene.
quarter Enrollment achieve initial SELECT-AML-X in the to with we CR XXXX from the the data SELECT-MDS-X data in SELECT-MDS-X SELECT-AML-X Phase are enrollment Phase track the planned fourth trial support and and the II XXXX. readouts from numbers of third necessary are trials to data on quarter both the ongoing, of and the in III pivotal
and consistent with observed patients continue overexpression, XX% expectations. RARA AML we've patients screen As for both XX% positive that higher-risk with trials, are approximately to of we patients MDS our for of
significant segments existing that AML are sizable options. patient by believe tamibarotene market the address of addressing and As by has such, we a populations underserved opportunity high-risk unfit MDS the potential to who continue to
support to that data the compelling improve could tamibarotene addition have of our the standard-of-care. belief of upon outcomes We the
activity which with consistently meaningful tamibarotene demonstrated evaluated multiple trials, have past in benefit. the Over we've for several potential years, clinical
and additive study evaluating with favorable time venetoclax, year to of our no complete our with Most regimen azacitidine and high rapid Phase triplet last lead-in safety in the tolerability recently, late AML in response myelosuppression. demonstrated with as we II response portion combination composite announced rates tamibarotene
these between tamibarotene's patient AML profile targeted similarities us MDS date, these gene the confidence potentially overexpression. populations give we've patient identifiable and and for new with Given biologically results differentiated are AML standard-of-care seen could people the benefit supportive that readily and MDS to establish populations a RARA data and that across
therapies need emphasizing It's agents, HMAs, in decade. tamibarotene. or MDS, also have and with worth no higher-risk beyond Starting be unmet that AML MDS over addressed approved been well the sizable in a by high-risk new there may hypomethylating
median with provides agent, months. clinical of standard-of-care like MDS existing of attributed XX.X HMA population and higher-risk overall an be patient with to may The efficacy just limited the heterogeneity. in CR genetic an a This survival and use non-targeted rate XX% a unselected a
same benefits also unique with provides time, approximate safety differentiation RARA who who our generally targeted frail overexpression tamibarotene well to address readily test approach a present well-tolerated generally blood using biologically particularly specifically the simple is which from can opportunity this At designed XX% elderly be patients and with identified profile, population. and assay. this suited a for the Tamibarotene of a to gene
As in overexpression. patients trial, in a newly of included key we overall the azacitidine XXX high-risk with patients the study of a response primary now plus placebo-controlled reminder, with initial MDS is as a in our the The diagnosed secondary combination endpoint. tamibarotene rate in study survival RARA complete are SELECT-MDS-X evaluating double-blind, III Phase endpoint
or FDA CR endpoint quarter, an efficacy As we of described feedback rate last to appropriate full use either our primary approval. continues as for support accelerated recent
the could benefit, future, the clinical That tamibarotene receives a confirm MDS-X full separate a select endpoint study study. addition confirmatory accelerated also to support need as for approval survival the avoiding approval, in to said, if of potentially the allow in secondary overall key same
XXX higher-risk select protocol, primary current endpoint. patients to the XXX Under supporting the trial including initial patients, will total of a MDS-X MDS enroll newly diagnosed the
plan in quarter this XXXX. report We're necessary endpoint to third support the to and patients CR CR quarter the enrollment to year data complete approval of fourth on of a track initial using pivotal in of the
where recent roughly patients AML, Phase evaluating the AML SELECT-AML-X patients one-third are RARA current all to do unfit of in not tamibarotene newly moving trial in AML, virtually we Now, to unfit respond newly relapse. eventually advancements AML diagnosed in II and overexpression. the standard-of-care diagnosed patients with on Despite
And important to segment, is who XX% believe overexpression. opportunity for as MDS, need there to approximately patient for existing identifiable an RARA a by tamibarotene AML we unmet address continue in sizable are
with evaluate The randomized the Patients X:X in CR/CRI alone randomized newly endpoint. the ongoing to CR with or rate tamibarotene in portion SELECT-AML-X into study designed of primary ven/aza of arms XX the rate two safety efficacy II and Phase compared were AML the ven/aza, to combination patients. as approximately is unfit diagnosed the composite treatment
direct understanding In of to with the will patients the help plus ven/aza, in treated data performance believe doublet in from triplet XXXX. RARA overexpression we our report versus this alone of this of compared with data the year, advance fourth of of quarter may This inform the in regimen tamibarotene we first additional to trial. the AML be the in expect triplet ven/aza and comparison initial of sharing
of of our remain for ATO. ongoing significant is current by of Now, of the turning which an to potential We standard-of-care the evaluated dose encouraged form the burden use includes to intravenous alleviate ATO confirmation study. APL that the XXXX, novel being in
rate effective lasts a infusions to year, highly four requiring up it is over of XXX which ATO two XX%, over nearly cure burdensome hours. patients, offering a each is IV treatment While to of for highly
By while and oral regimen reducing can we providing effective an ATO form health and oral costs we offer increasing that believe utilization. of an access is also care
year, and APL. confirmation gather look continue further timing of study this from in we data PK development the dose for providing in to the to XXXX the We path will evaluation in which of study include registration-enabling an update second half a and forward
cancer ASCO pancreatic encouraging from new Meeting clinical types Ib of wide combinations. of presented selective we in XXXX Finally, development CDKX potential in June, HR-positive data which of the range and XXXX, and of demonstrates in Annual significant at inhibition Phase the tumor and a supports further trial breast the
leaders clinicians standard-of-care, to warm that received observed the tolerability by respond reception well are in from the profile. heavily promising unlikely encouraged and are predictable, a as well-managed the key populations to opinion who data as pretreated These activity
ongoing look out-licensing and in We believe time the this future. an at update exploration of support appropriate development the our data providing further strongly these to program support to forward of opportunities
call I our like to the Jason? results. financial Chief quarter to second our would turn Jason, over review Financial now Officer, to
